Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 101
- Registration Number
- NCT00884312
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00721734
- Locations
- 🇺🇸
University of California- San Francisco, San Francisco, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Relapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00603447
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 164
- Registration Number
- NCT00530816
- Locations
- 🇺🇸
Therapeutic Research Institute of Orange County, Laguna Hills, California, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
- Conditions
- Renal CancerLymphomaNon-small Cell Lung CancerSolid TumorsOvarian CancerSmall Cell Lung CancerMultiple Myeloma
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 184
- Registration Number
- NCT00531284
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 312
- Registration Number
- NCT00511238
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Northwest Cancer Center, Houston, Texas, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
- Conditions
- Waldenstrom's MacroglobulinemiaNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT00150462
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.